Evidence map›Paper›PMID 40732303›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis.

Ray Manneh, Javier Molina-Cerrillo, Guillermo de Velasco, Linda Ibatá, Susan Martínez, Álvaro Ruiz-Granados, Teresa Alonso-Gordoa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ray MannehMedical Oncology Department, Sociedad de Oncología y Hematología del César, Valledupar 200001, Colombia.
Javier Molina-CerrilloMedical Oncology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0003-4616-0598
Guillermo de VelascoMedical Oncology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Linda IbatáEpidemiology Department, EpiThink Health Consulting, Bogotá 110231, Colombia.ORCID 0000-0002-7191-7313
Susan MartínezEpidemiology Department, EpiThink Health Consulting, Bogotá 110231, Colombia.
Álvaro Ruiz-GranadosMedical Oncology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
Teresa Alonso-GordoaMedical Oncology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-8966-7236

Funding

Hospital Universitario Ramón y Cajal None
6 · The paper itself

Abstract

PARP inhibitors (PARPi), alone or in combination with androgen receptor signaling inhibitors (ARSi), have shown clinical benefit in metastatic castration-resistant prostate cancer (mCRPC), particularly in tumors with homologous recombination repair (HRR) gene alterations. Recent data from the TALAPRO-2 trial complete the current evidence on PARPi-ARSi combination strategies in this setting.

Indexed as

DNA repair alterationsmetastatic castration-resistant prostate cancerPARP inhibitorsprecision oncology

Identifiers

PMID40732303
PMCPMC12298444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.